MarketCap
Facebook
X
Telegram
Veru Net Income | VERU
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Veru
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.7 M | -37.8 M | -93.2 M | -38.7 M | 7.39 M | -19 M | -12 M | -23.9 M | -6.61 M | 345 K | 4.35 M | 2.43 M | 14.3 M | 15.3 M | 5.4 M | 6.74 M | 6.54 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.3 M | -93.2 M | -11.2 M |
Quarterly Net Income Veru
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.95 M | -2.74 M | -5.33 M | -5.33 M | - | -7.33 M | -7.9 M | -8.95 M | - | -11 M | -10 M | -8.28 M | - | -12.5 M | -33.8 M | -38.7 M | -42.8 M | -22.2 M | -14.2 M | -6.38 M | 11.7 M | -2.69 M | -2.85 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | -3.31 M | -3.31 M | -3.31 M | -3.31 M | -2.15 M | -2.15 M | -2.15 M | -2.15 M | -4.26 M | -2.68 M | -790 K | -4.26 M | -1.37 M | -1.75 M | 570 K | -1.37 M | 1.49 M | 703 K | 1.17 M | 1.49 M | 805 K | -566 K | 1.16 M | 805 K | 1.46 M | 6.59 M | 727 K | 1.46 M | 3.53 M | 7.11 M | 2.55 M | 3.53 M | 2.66 M | 884 K | 417 K | 2.66 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.2 M | -42.8 M | -2.81 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Evoke Pharma
EVOK
|
-5.35 M | - | - | $ 36.6 M |  USA |
 |
HEXO Corp.
HEXO
|
-1.07 B | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-466 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-14.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
-2.9 M | $ 3.38 | 0.14 % | $ 1.3 B | Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | - | - | $ 2.06 B |  France |
 |
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.41 M | $ 8.46 | 0.29 % | $ 126 M | USA |
 |
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-8.32 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M |  Irlanda |
 |
Jupiter Wellness
JUPW
|
-68.2 M | - | - | $ 33.6 M | USA |
 |
Evolus
EOLS
|
-51.6 M | $ 8.88 | 1.14 % | $ 572 M | USA |
 |
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-90.4 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
-30.4 M | - | - | $ 150 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-21.5 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Harrow Health
HROW
|
-5.14 M | $ 37.27 | 3.84 % | $ 1.37 B | USA |
 |
Rockwell Medical
RMTI
|
-5.31 M | $ 8.17 | 5.42 % | $ 294 M | USA |
 |
Zomedica Corp.
ZOM
|
-81.9 M | - | -0.21 % | $ 98 M | USA |
 |
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.18 M | $ 1.31 | 3.0 % | $ 2.21 M | USA |
 |
Bausch Health Companies
BHC
|
157 M | $ 6.32 | 0.32 % | $ 2.34 B | Canada |
 |
Emergent BioSolutions
EBS
|
52.6 M | $ 5.91 | 0.68 % | $ 316 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.19 M | $ 0.9 | 2.03 % | $ 3.86 M |  China |
 |
OrganiGram Holdings
OGI
|
-45.4 M | $ 1.22 | 0.79 % | $ 116 M | Canada |
 |
TherapeuticsMD
TXMD
|
-569 K | $ 2.22 | 2.03 % | $ 25.7 M | USA |
 |
Perrigo Company plc
PRGO
|
-1.43 B | $ 14.48 | 2.84 % | $ 2.01 B | USA |
 |
Relmada Therapeutics
RLMD
|
-57.4 M | $ 4.33 | 0.22 % | $ 171 M | USA |
 |
SCYNEXIS
SCYX
|
-8.61 M | $ 5.39 | 1.63 % | $ 269 M | USA |
 |
Solid Biosciences
SLDB
|
-174 M | $ 9.77 | 4.22 % | $ 855 M | USA |
 |
Canopy Growth Corporation
CGC
|
-263 M | $ 1.0 | 1.9 % | $ 298 M | Canada |
 |
cbdMD
YCBD
|
-2.04 M | $ 0.5 | 0.58 % | $ 2.01 M | USA |
 |
ProPhase Labs
PRPH
|
-14.7 M | - | - | $ 5.07 M | USA |
 |
Aurora Cannabis
ACB
|
1.59 M | $ 4.01 | 0.12 % | $ 220 M | Canada |
 |
Organogenesis Holdings
ORGO
|
37 M | $ 1.74 | 0.57 % | $ 221 M | USA |
 |
Pacira BioSciences
PCRX
|
7 M | $ 25.76 | 0.75 % | $ 1.15 B | USA |
 |
Sundial Growers
SNDL
|
-15.8 M | $ 1.36 | 0.37 % | $ 351 M | Canada |
 |
Tilray
TLRY
|
-2.19 B | $ 4.59 | 0.44 % | $ 4.09 B | Canada |